Live
- Bulls roar on Dalal Street, Sensex and Nifty up over 2 pc
- Over 880,000 people displaced in Lebanon, food security deteriorates: UN
- BGT 2024-25: Bumrah picks 4-17 as Australia trail India by 83 runs in 17-wicket day
- Calcutta High Court stays order on demolition of hotels in Bengal’s Mandarmani
- AP Legislative Council Approves Key Bills
- WhatsApp Update: WhatsApp Rolls Out Group Mentions in Status Updates
- Czech PM, European Council President-elect discuss cooperation, EU priorities
- 47 killed, 22 injured in Israeli airstrikes on Lebanon's Baalbek-Hermel
- Chandrababu Advocates for Balanced Governance and Development in Andhra Pradesh
- Our 6 free services in Delhi pinching rivals: Kejriwal at 'Revadi par Charcha' campaign
Dr Reddy's reports Rs 570 crore loss for Q3
Profits impacted due to trigger-based impairment charge taken on a few products
Hyderabad: Dr Reddy's Laboratories Limited's suffered nearly Rs 570 crore loss for the quarter ended December 31 against Rs 485 crore profit after tax during the corresponding period of FY19, the company said on Monday. Revenues for the quarter under discussion was up by 14 per cent to Rs 4,384 crore against Rs 3,850 crore in Q3 of last fiscal.
Co-Chairman and MD, GV Prasad said, "The current quarter performance has been good across all our businesses and we achieved strong EBITDA margins.
The profits were impacted due to trigger-based impairment charge taken on a few products including Nuvaring. We continue to focus on execution and have made significant progress on quality systems and operational efficiencies."
Q3 FY20 financials include an impairment charge of Rs 1,320 crore million on some of the Company's products forming part of Global Generics and Proprietary Products segments, the drug maker said.
In December 2019 there had been a generic launch and an authorised generic launch for the product Nuvaring, which has led to a considerable erosion in the value of this product for the company, and accordingly the drug maker has taken an impairment charge of Rs 110 crore
"In addition to this, considering the current market dynamics, we have taken an impairment charge of Rs 210 crore on the intangibles pertaining to other products. In total, we have taken an impairment of Rs 1,320 crore on the intangible assets for this quarter," it said.
Revenues from Global Generics segment was reported at Rs 3,590 crore, year-on-year growth of 15 per cent, primarily driven by Europe, emerging markets and India.
Revenues from North America was at Rs 1,600 crore, a year-on-year growth of eight per cent the company launched five new products (Bortezomib injection, Doxercalciferol, Deferasirox dispersable tabs, Deferasirox film coated tabs, Sodium Nitroprusside injection) during the quarter in the US market.
Revenues from Emerging Markets was Rs 920 crore and India at Rs 720 crore. Revenues from Pharmaceutical Services and Active Ingredients was reported at Rs 690 crore a growth 16 per cent over the same quarter last year.
Dr Reddy's spent Rs 390 crore towards Research and Development expenses during October-December quarter.
